Over the past six months, psychologist Tom Hildebrandt has seen a surge in patients with eating disorders who are using popular weight loss drugs like Novo Nordisk A/S‘ (NYSE:NVO) Wegovy (semaglutide) or Eli Lilly And Co’s (NYSE:LLY) Zepbound (Tirzepatide). Hildebrandt, who leads Mount Sinai’s Center of Excellence in Eating and Weight Disorders, noted that these drugs, despite their success in diabetes and weight loss treatments, are causing some users to develop anorexia-like symptoms. These medications, part of the GLP-1 class of drugs, including Novo Nordisk’s Ozempic and Eli Lilly’s Mounjaro, work by mimicking a hormone called glucagon-like peptide 1, which curbs hunger and regulates blood sugar levels. Also Read: Craze For Ozempic And Zepbound ...